ALK and non-small cell lung carcinoma: NSCLC is a disease that is characterized by driver mutation-defined molecular subsets, and alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and KRAS are major oncogenic drivers in NSCLC16.